Kneu Health

What Kneu Health does

Kneu Health is a UK-based digital health company developing a precision neurology platform that transforms smartphones into clinical-grade continuous monitors for neurodegenerative conditions, primarily Parkinson's disease and dementia. The platform captures time-series neurological data via smartphone sensors and uses AI models to generate digital biomarkers — including an FDA-cleared Parkinson's tremor measurement module — that quantify disease progression and motor symptoms between clinic visits. A six-month deployment at Cedars-Sinai with 104 Parkinson's patients captured over 46,000 data points, and clinicians reported improved early intervention and disease insight from the resulting continuous readouts.

The company sells on a B2B subscription or licensing basis to large U.S. health systems, with anchor deployments at Cedars-Sinai and Mass General Brigham following FDA clearance. Distribution is enterprise field sales, supported by clinical validation publications, accelerator participation (Texas Medical Center Innovation Accelerator), and industry recognition including an SXSW £100,000 prize and HSJ Partnership Awards recognition. In October 2025, Kneu Health closed a $5.6 million oversubscribed seed round co-led by Oxford Science Enterprises and Cedars-Sinai to fund U.S. expansion and enhancement of dementia monitoring capabilities, and in early 2026 expanded its leadership team with a U.S. General Manager and Director of Partnerships to scale enterprise deployment.

Revenue mechanics are not publicly disclosed, but the commercial model is quote-based enterprise licensing, with a customer base presently concentrated among a small number of marquee U.S. health systems. The company is private, founded in 2022, headquartered in London, and operates with 11-50 employees. AI capability is positioned as the core technical differentiator, anchored by a proprietary clinical dataset and FDA-cleared measurement module, though the underlying model architecture and data flywheel mechanics are not transparently documented in available sources.

Name

Kneu Health

Legal name

Kneu Health

Website

https://kneu.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Kneu Health is a London-based digital health company that uses AI and smartphone sensors to deliver FDA-cleared, continuous remote monitoring for Parkinson's and dementia patients, sold on a subscription basis to U.S. health systems such as Cedars-Sinai and Mass General Brigham.

Ownership category

akta.pro rank

Product category

Digital Health / Neurology Monitoring Software

NAICS

Other Computer Related Services (541519)

SIC

Surgical & Medical Instruments & Apparatus (3841)

akta.pro primary industry

Neurology RPM (epilepsy, Parkinson’s, MS monitoring) (HLALAFAJ)

akta.pro secondary industry

Neurology Telemedicine Platforms (HLALAGAC)

Keywords

• Neurology care platform
• Digital biomarkers
• Remote patient monitoring
• Smartphone diagnostics
• Parkinson's monitoring

Headquarters

HQ city

London

HQ country

United Kingdom

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Neurology Monitoring Platform (B2B Health System Licensing): Kneu Health provides its FDA-cleared smartphone-based neurology monitoring platform to health systems (hospitals, neurology departments) on a licensing or subscription basis, generating recurring revenue per deployment or per monitored patient.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Core offering

Kneu Health provides an FDA-cleared, smartphone-based precision neurology platform that uses AI models and digital biomarkers to continuously monitor patients with Parkinson's disease and dementia. The platform captures large volumes of objective neurological data via patients' smartphones and delivers clinical insights to health systems, enabling earlier intervention, objective symptom tracking, and remote disease management within hospital neurology departments.

Product overview

Kneu Health offers a precision neurology platform designed as a unified system for monitoring neurodegenerative conditions. The core platform provides continuous smartphone-based monitoring, with the FDA-cleared Parkinson's Tremor Measurement Module serving as a specialized add-on for objective tremor assessment. Both components leverage AI-powered biomarkers to support earlier intervention in Parkinson's and dementia.

Differentiator

Problem solved

Functional benefit

Products and services

• Precision Neurology Platform
• Parkinson's Tremor Measurement Module

Quantifiable outcome

• Captured 46,000+ data points across 104 patients in a six-month clinical deployment
• +2 more outcomes

Named customers2 records

Segments1 record

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature3 records

Partnerships

Three partnerships are on record, tiered core, major and supporting.

• Cedars-SinaicoreStrategic or Co-development PartnerCedars-Sinai conducted a six-month clinical deployment of Kneu Health's precision neurology platform with 104 Parkinson's disease patients, capturing over 46,000 data points and demonstrating improved early intervention and disease insight.
• Mass General BrighammajorStrategic or Co-development PartnerMass General Brigham is a prominent health system partner deploying Kneu Health's smartphone-based neurological monitoring platform as part of U.S. expansion efforts alongside Cedars-Sinai.
• Texas Medical Center Innovation AcceleratorsupportingStrategic or Co-development PartnerKneu Health graduated from the Texas Medical Center Innovation accelerator program, which supported the development and scaling of its neurological monitoring platform for deployment across U.S. health systems.

Scale indicators3 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Cala Health: Cala Health offers FDA-cleared wearable therapies and digital monitoring for essential tremor and Parkinson's disease, sold into US health systems and movement-disorder clinics — overlapping indication, regulatory pathway, and customer profile with Kneu's tremor measurement module.
• NeuroPace: NeuroPace's RNS System is an FDA-cleared implantable neurostimulation device for refractory epilepsy with continuous brain-monitoring data — comparable as an FDA-cleared, data-generating neurology platform deployed inside US health systems, though implanted rather than smartphone-based.
• Rune Labs: Rune Labs' StrivePD platform uses Apple Watch sensors and FDA-cleared algorithms to continuously monitor Parkinson's patients for tremor, dyskinesia, and gait — directly comparable to Kneu's smartphone-based Parkinson's monitoring approach and target buyer (US neurology departments).
• Empatica: Empatica develops FDA-cleared wearable sensors and a smartphone-linked monitoring platform (EpiMonitor) for neurological conditions including seizure detection, marketed to health systems and clinical trials — comparable in wearable/smartphone-based neurological monitoring and FDA-cleared business model.

Broad incumbents

• iRhythm Technologies: iRhythm sells FDA-cleared wearable cardiac monitoring (Zio) to US health systems on a recurring per-diagnostic license model — a relevant comparable for Kneu's B2B health-system RPM licensing motion and FDA-cleared wearable-to-cloud diagnostic architecture, though in cardiology rather than neurology.
• GE HealthCare: GE HealthCare is a broad incumbent medical device and digital health vendor with neurology imaging, ICU patient monitoring, and enterprise hospital IT installed across the same US academic health systems Kneu is targeting — relevant as both a competitor for neurology monitoring budgets and a potential OEM/channel partner.
• Medtronic (Neuromodulation / DBS): Medtronic's neuromodulation business sells FDA-cleared deep brain stimulation (DBS) systems and Activa PC for Parkinson's and other movement disorders, marketed to US academic neurology and neurosurgery centers — a broader incumbent alternative for advanced Parkinson's disease management.

Emerging players

• Akili Interactive: Akili Interactive developed EndeavorRx, the first FDA-cleared prescription video game digital therapeutic, and has explored cognitive/neurological indications — comparable as a software-as-medical-device company pursuing FDA clearance for cognitive and neurological conditions.
• Cognito Therapeutics: Cognito Therapeutics is developing prescription digital therapeutics (audio-visual gamma stimulation) for Alzheimer's disease and other neurodegenerative conditions — overlapping in neurodegenerative disease focus and FDA-regulated digital therapeutic model.
• Click Therapeutics: Click Therapeutics develops prescription digital therapeutics across neurology and psychiatry indications, partnering with pharma and pursuing FDA clearance — comparable as an emerging software-based therapeutics platform targeting neurological disease, though delivered as a treatment rather than a monitoring tool.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/kneuhealth

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds1 record

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Kneu Health